Idiopathic pulmonary fibrosis is a progressive lung disease with complex pathophysiology and fatal prognosis. Macrophages (MF) contribute to the development of lung fibrosis; however, the underlying mechanisms and specific MF subsets involved remain unclear. During lung injury, two subsets of lung MF coexist: Siglec-F hi resident alveolar MF and a mixed population of CD11b hi MF that primarily mature from immigrating monocytes. Using a novel inducible transgenic system driven by a fragment of the human CD68 promoter, we targeted deletion of the antiapoptotic protein cellular FADD-like IL-1b-converting enzyme-inhibitory protein (c-FLIP) to CD11b hi MF. Upon loss of c-FLIP, CD11b hi MF became susceptible to cell death. Using this system, we were able to show that eliminating CD11b hi MF present 7-14 days after bleomycin injury was sufficient to protect mice from fibrosis. RNA-seq analysis of lung MF present during this time showed that CD11b hi MF, but not Siglec-F hi MF, expressed high levels of profibrotic chemokines and growth factors. Human MF from patients with idiopathic pulmonary fibrosis expressed many of the same profibrotic chemokines identified in murine CD11b hi MF. Elimination of monocyte-derived MF may help in the treatment of fibrosis. We identify c-FLIP and the associated extrinsic cell death program as a potential pathway through which these profibrotic MF may be pharmacologically targeted. 
Macrophages (MF) are known to be involved in fibrogenesis. Lung MF numbers are elevated both in patients with idiopathic pulmonary fibrosis (IPF), a progressive lung disease with complex pathophysiology and fatal prognosis (1, 2) , and in murine models of pulmonary fibrosis (3, 4) . However, the mechanisms by which MF impact fibrosis are unclear. The objectives of this study were to determine the roles played by MF subsets in the development of lung fibrosis and to determine if fibrosis could be attenuated by promoting MF apoptosis.
During homeostasis, there are two main types of MF in the murine lung: resident Siglec-F hi CD11b
lo MF that reside in the alveolar space, and CD11b hi Siglec-F lo MF that occupy the lung interstitium. Siglec-F hi MF (often called resident alveolar MF and highly expressing CD11c) arise during embryogenesis, populate the airspaces immediately after birth, and self-renew throughout life without replacement from circulating monocytes (5) (6) (7) (8) (9) . CD11b hi MF (often called interstitial MF [IMs] ) also arise during embryogenesis, but are restricted to the lung interstitium and found in much lower numbers than Siglec-F hi alveolar MF (5, 6) .
After lung injury, MF numbers expand in both the alveolar and interstitial compartments. Studies using lung-shielded bone marrow chimeras, targeted MF or monocyte depletion, and CCR2
2/2 mice all suggest that monocytes recruited from the circulation are the dominant source of new MF (often termed recruited MF) after injury (10) (11) (12) . Much like homeostatic resident IMs, newly recruited MF express high levels of CD11b and low levels of Siglec-F. Accordingly, during acute inflammation, three main MF populations exist in the lung. These include two types of resident MF (Siglec-F hi CD11b lo alveolar MF and CD11b hi SiglecF lo IMs), present before onset of inflammation and that remain throughout its course, and a third population of recruited MF in the alveolus and interstitium (also CD11b hi SiglecF lo ) that derive from monocytes and are only present in the context of disease.
Studies that separate MF subsets are imperative for clarifying their roles in fibrogenesis (13) . However, a lack of tools for distinguishing and manipulating MF subsets had previously hampered this objective. The identification of reliable cell surface markers that distinguish resident alveolar MF from other subtypes constitutes a recent advance (7, 10, 14, 15) . In addition, we have developed a new transgenic system to target MF subsets (16) . Whereas traditional drivers of cre recombinase (cre) constitutively affect all lung MF starting early in development, we recently described a system in which CD11b hi MF can be selectively targeted in a time-dependent fashion. Targeting is achieved using a fragment of the human CD68 promoter coupled with the reverse tetracycline-controlled transactivator (hCD68rtTA). Administration of doxycycline to these animals rapidly activates tetracycline-responsive elements in CD11b
hi IMs and recruited MF. Siglec-F hi MF are not affected (16) . As described subsequently here, we leveraged this new method to selectively manipulate the survival of CD11b hi MF during bleomycin-induced lung injury and test their contribution to fibrogenesis.
Appropriately timed apoptosis of lung MF is beneficial for resolution of inflammation and effective tissue repair. MF resistance to apoptosis is implicated in the development of murine fibrosis and human IPF (17) . We have previously demonstrated that CD11b hi MF are recruited to the alveolar space during LPS-induced lung injury, but disappear within 2 weeks as a consequence of cell surface Fas receptor (Fas)-FasL-mediated cell death (10) . In comparison, MF numbers remain elevated for over 6 weeks after bleomycin-induced lung injury and fibrosis. Eventual decline in MF number correlates with resolution of fibrosis (4) . Treatment of mice with TNF-a after bleomycin injury accelerates MF decline and hastens the resolution of fibrosis (4).
FasL and TNF-a both activate the extrinsic cell death pathway. To induce cell death, this pathway requires the simultaneous presence of a death-inducing ligand, expression of the corresponding death receptor, and a permissive intracellular environment. Ligation of FasL or TNF-a to their cognate surface receptors triggers the transproteolytic cleavage of pro-caspase-8 homodimers to active caspase-8. Whereas low levels of active caspase-8 activate NF-kB and promote survival, higher levels trigger programmed cell death (18, 19) . Cellular FADD-like IL-1b-converting enzyme-inhibitory protein (c-FLIP) is a critical death effector domain-containing protein that restricts caspase-8 activation (20) (21) (22) (23) . Accordingly, loss of c-FLIP sensitizes murine and human MF to cell death (24) (25) (26) .
We hypothesized that deleting c-FLIP in CD11b
hi MF would promote their death and attenuate the development of fibrosis. We crossed hCD68rtTA mice with tet-OnCre and cFLIP fl/fl mice to create animals in which c-FLIP could be conditionally deleted in CD11b hi IMs and recruited MF upon administration of doxycycline. Deletion of c-FLIP sensitized MF to programmed cell death and specifically reduced CD11b hi MF numbers in the lungs. Moreover, deletion of c-FLIP in CD11b hi MF at both early (Day 1) and delayed (Day 7) time points significantly attenuated the development of fibrosis. Finally, using improved surface marker identification (7), we assessed the transcriptome of CD11b hi MF during bleomycin injury to identify potential mediators of their profibrotic function.
Methods

Animals
This study was approved and performed in accordance with the ethics guidelines of the Institutional Animal Care and Use Committee at National Jewish Health. cFLIP fl/fl mice (27) were provided by Dr. You-Wen He (Duke University, Durham, NC). Details on other strains are provided in the data supplement.
Bleomycin Injury
Bleomycin (TEVA Pharmaceuticals) was administered in a dose of 3 U/kg, adjusted for the weight of the mouse, in 50 ml of PBS. Bleomycin was instilled intratracheally using a modified gavage needle. Mice were sedated with isoflurane (Baxter) before intratracheal instillations.
Flow Cytometry
Cells were stained with surface antibody panels to identify myeloid populations and analyzed using an LSRII flow cytometer (BD) and FlowJo software (Tree Star) or sorted using Moflo XDP-100 with Summit v5.1 software (Beckman Coulter, Dako). Details can be found in the data supplement. 
Measures of Caspase Activation
Cells recovered from BAL 7 days after bleomycin were adhesion purified to select for MF. Caspase-Glo (Promega, Madison, WI) assays were used per the manufacturer's instructions to measure caspase activity. Details can be found in the data supplement.
Assessing Fibrosis
Immediately after death, static compliance, a measurement that reflects the static elastic recoil pressure of the lungs at a volume of 0.95 ml, was determined using flexiVent (SCIREQ). Lungs were perfused with PBS and the right lung was saved for hydroxyproline analysis (28) , or lungs were inflated with low-melt agarose, fixed in 10% formalin overnight, then paraffin embedded; 10-mm slices were stained with Trichrome and imaged with an Aperio system (Leica Biosystems).
RNA Isolation and RT-PCR
RNA was isolated from MF using the RNeasy micro kit (Qiagen) and DNase treated as instructed by the manufacturer. RNA was then processed for RNA-seq or RNA was reverse transcribed to cDNA using Superscript IV VILO Master Mix (Invitrogen) per the manufacturer's instructions for RT-PCR. Primer sequences in can be found in the data supplement.
RNA-Seq
Isolated total RNA from sorted cells was processed for next-generation sequencing library construction as developed in the NJH Genomics Facility for analysis with a Life Technologies Ion Proton next-generation sequencing platform. Details can be found in the data supplement.
Gene Expression Omnibus Data Sets
Microarray data from human MF (29) were obtained from the Gene Expression Omnibus (GEO; GEO accession no. GSE49072). Details can be found in the data supplement.
Statistical Analysis
Statistics for RNA-seq and GEO DataSet analyses were performed as described in the data supplement. For all other experiments, differences between two groups were examined using Student's unpaired t test. Differences among three or more groups were examined using ANOVA with Holm-Bonferroni's multiple comparison test post hoc analysis. A P value less than 0.05 was considered significant.
Results
CD11b
hi MF Account for the Increase in Total Lung MF after Bleomycin MF contribute to lung fibrosis; however, the discrete contributions of MF subsets remain unclear. To develop a framework for studying the MF subsets, we first quantified MF during the initiation of fibrosis. We measured CD11b hi MF and Siglec-F hi MF in BAL fluid and enzymatically digested lungs from bleomycin-treated mice, adapting previously published protocols (7, 10, 14, 15) ( Figure 1A ). For all subsets, MF were identified based on their coexpression of CD64 and MER proto-oncogene tyrosine kinase (Mertk), cell surface molecules that, together, are specific for MF (30, 31) . Notably, Ly6C
hi "inflammatory" monocytes express low CD64 and negligible Mertk, and were thus excluded by our MF gating strategy (see Figures E1A and E1B in the data supplement). High expression of Siglec-F was recently identified as a marker of resident alveolar MF (7), and use of Siglec-F and CD11b was sufficient to distinguish MF subpopulations in the lung at all time points ( Figure 1B) . In contrast, use of CD11b in conjunction with other markers failed to clearly separate CD11b hi MF as inflammation progressed ( Figures  E1C and E1D ). MF were examined in the first 2 weeks after injury, when fibrogenesis begins (4). Quantification of lung MF subsets revealed that CD11b hi MF were responsible for the increase in MF numbers in both the airspace and tissue compartments ( Figures 1C  and 1D ). To specifically induce death of CD11b hi MF and block their accumulation, we conditionally deleted c-FLIP (gene cflar) using our newly described hCD68rtTA system (16) . c-FLIP is a nonenzymatic caspase-8 homolog that dimerizes with caspase-8 and inhibits its proapoptotic activity. By crossing hCD68rtTA with tetOn-Cre and cFLIP fl/fl mice, we were able to generate triple-transgenic mice in which administration of doxycycline leads to inducible deletion of cflar in CD11b caspase-8 (initiator caspase in extrinsic cell death) and caspase-3 (downstream terminal executioner caspase). We also examined phenotypic changes associated with cell death: loss of plasma membrane integrity and loss of cell adherence. In brief, cFLIP D/D mice and cFLIP fl/fl littermate controls were treated with bleomycin, and BAL MF were isolated 7 days later and placed in culture. Doxycycline was added to delete c-FLIP and an activating a-Fas antibody was added to trigger the extrinsic cell death pathway. We deliberately chose a dose of a-Fas that triggered minimal Fas activation. The caspase-8 inhibitor, Z-IETD-FMK, was added to some wells as a negative control. As shown in Figure 2A , when doxycycline or a-Fas alone was added to cFLIP D/D MF there was no significant increase in caspase-8 activity. However, when a-Fas was added after doxycycline, caspase-8 activation increased. As anticipated, Z-IETD-FMK blocked this effect. Importantly, MF from littermate control mice (cFLIP fl/fl ) treated in parallel showed caspase-8 activity in response to a-Fas, but no additional effect of doxycycline ( Figure 2B ). Taken as a whole, these data demonstrate that death receptor ligation induces enhanced activation of caspase-8 when c-FLIP is deleted in lung MF.
To determine whether c-FLIP deletion would lead to downstream activation of caspase-3, ex vivo studies were repeated, again using BAL MF from bleomycin-treated cFLIP -Tomato mice were treated with bleomycin and then started on doxycycline at Day 7. At Day 10, lungs were collected, inflated, and frozen with optimal cutting temperature compound for histology. Double-stranded DNA breaks were labeled with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; green), and tissue sections were costained with CD68 (teal) and DAPI (blue), along with endogenous Tomato reporter (red). (Figures 3C-3F) . Importantly, early inflammation was similar between c-FLIP D/D and cFLIP fl/fl mice; neutrophil, eosinophil, and monocyte numbers were equivalent ( Figures E3A-E3D ). Dendritic cells, which are targeted by hCD68rtTA (16), also had similar numbers between Figures E3E-E3G) . Furthermore, we have previously shown that no CD45-negative cells activate hCD68rtTA (16), but we verified that fibroblasts were not targeted in our system by staining lung sections from bleomycin-treated reporter mice with a-smooth muscle actin ( Figure E4 ).
groups (
Because hCD68rtTA targets CD11b hi MF in the airspaces and tissue during inflammation (16), we separated CD11b hi MF by compartment to examine the effect of c-FLIP deletion. A fluorescently conjugated a-CD45 antibody was given intratracheally to bleomycin-treated mice immediately after being killed to selectively label MF in the airspaces (but not the tissues) (32) . BAL was performed 5 minutes later, followed by lung digestion. As expected, both Siglec-F hi MF and CD11b hi MF from BAL stained brightly with intratracheal a-CD45 ( Figure 3G ). Siglec-F hi MF present in lung digests also stained brightly with intratracheal a-CD45, confirming that Siglec-F hi MF existed exclusively in the alveolus. These data also demonstrate that lavage is inefficient in removing leukocytes from the alveolus, as previously shown (33) . Notably, when CD11b hi MF from lung digests were examined for a-CD45 labeling, there were two populations. The first stained brightly with a-CD45, indicating that these cells were from the alveolar compartment and represented recruited CD11b hi alveolar MF. The second population was a-CD45 dim, indicating that these CD11b hi cells resided in the tissues and were IMs. Results were not compromised by any bleomycinor BAL-induced damage of the tissue; intravenous a-CD45 given before death was not found in BAL, demonstrating that the lung tissue is intact ( Figure E3H ).
Careful examination of the a-CD45 dim (i.e., interstitial) and bright (i.e., alveolar) CD11b hi MF populations revealed that their side scatter (SSC) profiles were different ( Figure 3G ), as was expression of CD11c (data not shown). We therefore hypothesized that SSC and CD11c might serve as markers of tissue localization. Indeed, separating CD11b hi MF from lung digest using SSC versus CD11c isolated two populations ( Figure 3H ) that correlated highly with alveolar and tissue MF ( Figure 3I ). , animals were given doxycycline without bleomycin. Fibrosis was assessed 14 days later using lung physiology, histology, and hydroxyproline measurements. As shown in Figure 4A Figures 4C and 4D ). Taken together, these studies suggest that early deletion of c-FLIP from CD11b hi MF induces loss of CD11b hi MF and attenuates fibrogenesis.
Application of this technique to lung
As shown in Figure 1 , CD11b hi MF numbers in wild-type mice were increased 7 days after bleomycin; however, fibrosis in this system does not peak until Day 14 (4) . Ergo, we hypothesized that the CD11b Figure 4E ), which were again protected from the development of fibrosis, as demonstrated by improved lung compliance and decreased hydroxyproline content ( Figures 4F and 4G ). These findings suggest that CD11b hi MF present in the lungs 7-14 days after bleomycin promote the development of fibrosis. Figure 5A ). In contrast, Siglec-F hi MF were remarkably similar, whether collected from naive or bleomycintreated lungs. The most up-and downregulated genes are shown in the data supplement ( Figure E5 ). To validate our sort strategy, we confirmed that all MF showed high expression of commonly accepted MF markers and low expression of genes associated with lymphocytes, dendritic cells, neutrophils, and eosinophils ( Figure 5B ).
Many researchers frame MF in terms of having an "M1" or "M2" polarization, where M2 is associated with prorepair or profibrotic MF. However, we and others have questioned the ability of a binary system to describe the complexities of MF polarization, particularly in vivo (34) (35) (36) . RNA-seq showed that CD11b hi and Siglec-F hi MF from bleomycin-treated mice expressed markers of both M1 and M2 polarization ( Figure E6) . Expression of these markers by the two MF subtypes was largely similar. In aggregate, the transcriptomal profiles of CD11b hi and Siglec-F hi MF highlight the problem of ascribing a facile polarization state to MF populations in vivo. With this in mind, we sought to explore pathways that relate directly to fibrosis.
Closer inspection of the RNA-seq data showed that CD11b hi MF had higher expression of epithelial and fibroblast proliferative factors (37), including hepatocyte growth factor, as well as higher expression of matrix-remodeling proteins ( Figure E7A ). More strikingly, CD11b hi MF showed elevated expression of numerous chemokines compared with Siglec-F hi MF ( Figure 6A ), many with established profibrotic functions, including ccl2, ccl12, and ccl24 (38).
Human BAL MF from Patients with IPF Show High Expression of Profibrotic Chemokines
To determine if human and murine MF from fibrotic lungs share common features that drive fibrosis, we used publically available gene-array data from the GEO to assess the overlap of our murine CD11b hi MF profibrotic MF with the signatures of BAL MF from patients with IPF (29) (GEO accession no. GSE49072). Most structural cell mitogens and matrixremodeling proteins, although upregulated in murine CD11b hi MF, were not upregulated in BAL MF from patients with IPF ( Figure E7B ). However, profibrotic chemokines were strongly upregulated in BAL MF from patients with IPF ( Figure 6B ); this overlapped with a group of murine homologs expressed by CD11b hi MF. Interestingly, this overlap comprised chemokines that recruit fibrocytes to the lung and promote fibroblast survival, including ccl2 and ccl24 (39) (40) (41) . Although the human alveolar MF were obtained from patients with established fibrosis (rather than the initiation phase), and were not divided into resident versus recruited subsets, these data suggest that one common mechanism by which murine and human MF contribute to the development of fibrosis may be elevated production of profibrotic chemokines that stimulate recruitment and survival of fibrocytes and fibroblasts.
In summary, we show that murine CD11b hi MF promote the development of lung fibrosis after bleomycin. Using hCD68rtTA, we were able to delete c-FLIP in CD11b
hi MF and induce CD11b hi MF death after bleomycin. Loss of CD11b hi MF was sufficient to prevent the development of fibrosis. RNA-seq suggests that this profibrotic function may be mediated through production of profibrotic factors, including chemokines specifically expressed by CD11b hi MF.
Discussion
MF in the lungs can be divided into multiple subsets. Identifying their relative contributions to the development of fibrosis has become an important area of research.
In this study, we provide a clear flow cytometry strategy to separate resident alveolar MF (Siglec-F hi ) from other MF present during fibrosis (CD11b hi ), the majority of which are recruited MF that arise from immigrating monocytes. Using the novel hCD68rtTA system (16), we were able to discretely target CD11b hi MF without affecting Siglec-F
hi MF, and demonstrate the specific contribution of CD11b hi MF to the development of bleomycin-induced fibrosis.
Using established MF markers, CD64 and Mertk (30, 31), we could clearly select MF within the BAL or lung digest. Recruited CD11b hi MF in the alveolus adopt a resident-like phenotype over time, including down-regulation of CD11b, which can make their distinction difficult during the late phases of inflammation (42) . However, we have identified high Siglec-F as a persistent marker of resident alveolar MF (7), and were able to leverage this may be adapted further, for example, by delaying doxycycline until after fibrosis has developed to test whether inducing CD11b
hi MF death will accelerate the resolution of established fibrosis.
RNA-seq suggested multiple means by which CD11b hi MF might exert a profibrotic function. We observed that
CD11b
hi MF are the predominant MF source of profibrotic chemokines, matrix remodeling proteins, and growth factors for epithelial cells and fibroblasts. Interestingly, we found that elevated expression of fibrogenic chemokines was echoed in human lavaged MF from patients with IPF. In particular, ccl2 and ccl24 were strongly upregulated in murine CD11b hi MF isolated from bleomycin-treated mice and in human MF from patients with IPF. In humans and mice, these chemokines can directly recruit fibrocytes to the lung. CCL24 also promotes the survival of fibroblasts, whereas CCL2 stimulates their proliferation and production of collagen (39, 40, 44, 45) . CCL2 and CCL24 correlate with progression and severity of human IPF (46, 47) . We speculate that production of CCL2 and CCL24 by CD11b hi MF is one mechanism by which CD11b hi MF promote the development of fibrosis, which can be clarified in future studies. In addition, it is notable that the addition of exogenous apoptotic cells accelerates the resolution of fibrosis in mice (48) hi MF may also be fruitful targets. We speculate that CCL2 and CCL24 are key profibrotic chemokines. Although initial testing of a-CCL2 immunotherapy was halted due to complications (49), a-CCL24 immunotherapy is in development, and may be useful in the treatment of IPF.
Because much of the MF literature in lung fibrosis has focused on MF polarization, it is important to note that RNA-seq did not identify a clear M1 or M2 polarization in Siglec-F hi or CD11b hi MF. Although individual genes can be selected to argue for a specific polarization (i.e., Arg1), looking at the body of markers clearly demonstrates that both M1 and M2 pathways are Figure 6 . CD11b hi MF express a profibrotic signature, including high expression of multiple profibrotic chemokines, that is validated in human MF from patients with idiopathic pulmonary fibrosis (IPF). (A) Heat maps showing expression of genes encoding chemokines. Unsupervised clustering was used to highlight associations between expression of these genes and MF subtypes. Raw expression is displayed on a log scale as average TPM per group (green-purple color scale) and scaled expression shows relative expression of each gene as the change from row mean scaled to a standard deviation of 1 (red-blue color scale). (B) Chemokines with significantly different expression in BAL MF from patients with IPF compared with normal volunteers were identified from publically available data in the Gene Expression Omnibus (accession no. GSE49072). Unsupervised clustering was used to highlight associations between expression of these genes and disease state. Scaled expression shows relative expression of each gene as the change from row mean scaled to a standard deviation of 1. Chemokines upregulated in both human IPF MF and murine CD11b hi MF compared with control human MF or murine SiglecF hi MF after bleomycin are highlighted in red. *Gene with no direct murine/human homolog. activated in lung MF. Although this could reflect the presence of discrete M1 and M2 polarized subpopulations within MF subtypes (testable by single-cell analysis), our data best support the view that a binary system is not capable of categorizing the complex MF present in disease states (34, 36) .
In contrast, separating subsets and studying functionality of MF provides important insight into disease pathology. We clearly show that CD11b hi MF drive fibrogenesis, whereas resident Siglec-F hi alveolar MF neither increase in number after bleomycin nor express high levels of profibrotic mediators. Nonetheless, our study is only a first step toward clarifying the complex MF subsets present in the lung during fibrosis. In the future, we anticipate that it will be possible to further divide CD11b hi MF into resident IMs and recruited alveolar and tissue MF. It is intriguing that naive IMs express many chemokines and matrix-remodeling factors that can be considered profibrotic. Because cell origin and tissue environment shape MF function, phenotype, and transcriptome (7, 50, 51) 
